- Oncology revenues up almost 300 per cent
- Full-year pre-tax loss to shrink
An extensive research and development (R&D) programme finally seems to have paid off for Hutchmed (HCM), the Hong Kong-based pharmaceutical group that operates mostly in mainland China. After reporting a pre-tax loss for the 2022 financial year, the company is now comfortably in the black in the first half.